CNBTF - Cannara Biotech Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
0.1325
0.0000 (0.00%)
At close: 4:02PM EDT
Stock chart is not supported by your current browser
Previous Close0.1325
Open0.1303
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.1325 - 0.1325
52 Week Range0.0800 - 0.1967
Volume32,717
Avg. Volume45,390
Market Cap62.574M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • PR Newswire

    Cannara Announces Appointment of New Chief Operating Officer

    VANCOUVER, Aug. 15, 2019 /PRNewswire/ - Cannara Biotech Inc. ("Cannara Biotech" or the "Company") (LOVE.CN) (OTCQB:LOVFF) (8CB.F), an emerging vertically integrated cannabis company focused on the cultivation and sale of dried premium cannabis and cannabis-infused products, today announced the appointment of Barry Laxer as Cannara's new Chief Operating Officer, effective August 14, 2019. "We are excited to welcome Barry to the leadership team, knowing his contributions will help accelerate our company to its next stage of growth," said Zohar Krivorot, President and CEO of Cannara. Barry will replace Evan Morris, who has helped bring the construction phase of our Farnham facility to completion.

  • CNW Group

    Cannara Biotech Inc. Reports Q3 2019 Results

    VANCOUVER , July 25, 2019 /CNW/ - Cannara Biotech ("Cannara" or the "Company") (LOVE.CN) (8CB.F) (OTCQB:LOVFF), an emerging vertically integrated cannabis company focused on the cultivation and sale of dried premium cannabis and cannabis-infused products, today announced financial results for the three month and nine month periods ended May 31, 2019. Closed a Global shopCBD.com Inc. financing in excess of $8 million to support the launch of the online e-commerce platform for the sale and distribution, in the US, of hemp-based CBD products. Subsequent to the quarter, the Company further strengthened its balance sheet with a $2.1 million private placement.

  • CNW Group

    Cannara Biotech Announces Non-Brokered Private Placement of 12,000,000 Common Shares

    Cannara Biotech Announces Non-Brokered Private Placement of 12,000,000 Common Shares

  • CNW Group

    Cannara Biotech Appoints Dr. Sara May to its Board of Directors

    VANCOUVER , May 24, 2019 /CNW/ - Cannara Biotech ("Cannara" or the "Company") (LOVE.CN) (8CB.F) (CNBTF), an emerging vertically integrated cannabis company focused on cultivation and cannabis-infused products, today announced the appointment of Dr. Sara May , PhD. Dr. May is recognized as an expert in the medical cannabis sector and will bring  additional skill sets and help strengthen  the Company's Board.

  • CNW Group

    Cannara Biotech Commences Trading on the OTCQB Market in the United States

    VANCOUVER , May 15, 2019 /CNW/ - Cannara Biotech ("Cannara" or the "Company") (LOVE.CN) (8CB.F) (CNBTF), an emerging vertically integrated cannabis company focused on the cultivation and sale of cannabis and cannabis-infused products to the Canadian and international markets, today announced its common shares are listed for trading on the OTCQB® Venture Market under the  trading symbol "CNBTF". The OTC operates financial markets for approximately 10,000 U.S. and global securities.  "Cannabis and hemp-CBD markets are global markets, with customers, vendors and investors domiciled across all major industrial nations," said Zohar Krivorot, President and CEO of Cannara.

  • CNW Group

    Cannara Biotech Reports Q2 2019 Results

    Cannara Biotech Reports Q2 2019 Results

  • CNW Group

    Cannara Biotech Appoints Jack Kay as New Board Director

    MONTREAL , April 8, 2019 /CNW/ - Cannara Biotech ("Cannara" or the "Company") (CSE: LOVE FRA: 8CB), an emerging vertically integrated cannabis company focused on cultivation and cannabis-infused products, today announced the appointment of Jack Kay as a Director on Cannara's Board, effective immediately. Mr. Kay is generally recognized as one of Canada's leading pharmaceutical executives, having held senior positions in a number of firms, including CEO of Apotex. "A strong and independent board is not only vital for a successful public company, it can serve as a competitive advantage in the battlefield of commerce and growth," said Zohar Krivorot, President and CEO of Cannara Biotech.

  • CNW Group

    Cannara Biotech Subsidiary Global shopCBD.com Raises in Excess of $8.8 Million to Fuel U.S. Hemp-CBD E-Commerce Platform

    With the recent passing of the 2018 Farm Bill in the U.S., CBD represents a developing sector with many vendors seeking national reach to U.S. customers. ShopCBD.com's strategy is to offer a wide variety of products from leading CBD brands, with competitive pricing and delivery times across the U.S. The rise in popularity for CBD products is driven by consumers seeking natural-based health & wellness solutions to treat various ailments from inflammation, anxiety to insomnia amongst many others.

  • CNW Group

    Cannara Biotech Shares to Begin Trading on the Frankfurt Exchange

    MONTRÉAL, Feb. 11, 2019 /CNW/ - Cannara Biotech Inc. ("Cannara Biotech" or the "Company") (LOVE.CN) (FRA:8CB), a vertically integrated cannabis company focused on cultivation and cannabis-infused products, today announced its common shares are listed for trading on the Frankfurt Stock Exchange under the trading symbol "8CB". The Frankfurt Stock Exchange is the tenth largest stock exchange in the world by market capitalization and third largest in terms of volume. "No doubt the world is becoming keenly interested in the global cannabis industry, and much of that enthusiasm and attention is turning towards Canadian companies who are at the forefront of innovating and leading this sector," said Zohar Krivorot, President and CEO of Cannara Biotech.